Biotech Specialty Pharma

Dendreon Corporation

3005 First Avenue
Seattle, WA 98121 USA
Click for website

Research Sector Biotech Specialty Pharma

Summary Description The company applies its expertise in antigen identification, engineering and cell processing to produce active cellular immunotherapy (ACI) product candidates designed to stimulate an immune response to cancer

Management Mitchell H. Gold, M.D., President and Chief Executive Officer and Director; Hans E. Bishop, Executive Vice President and Chief Operating Officer; Mark W. Frohlich, M.D., Senior Vice President, Clinical Affairs and Chief Medical Officer; Richard F. Hamm, Jr., Senior Vice President, Corporate Development, General Counsel, and Secretary; Gregory T. Schiffman, Senior Vice President and Chief Financial Officer

Click here for Financial Data
Keywords: immunotherapy, metastatic, sipuleucel-t, carcinoembryonic, hormone-refractory, immunotherapy, cellular immunity, breast, ovarian, colon, lung


Updated: Nov. 19, 2012


Dendreon Corporation (NASDAQ: DNDN), a Seattle-based biotechnology company, is focused on targeting cancer to transform lives through the discovery, development and commercialization of novel therapeu......view more

Products / Services

PROVENGE (sipuleucel-T) is the first autologous cellular immunotherapy to receive FDA approval for the treatment of asymptomatic or minimally symptomatic metastatic castrate resistant prostate cance......view more

Competitors / Substitutes / Alternatives

Biomira Inc (BIOM), Cell Genesys Inc (CEGE)...view more


Key elements of their business strategy include: maximizing speed to market of lead therapeutic vaccines, building a large and diverse product portfolio, retaining core commercialization rights, devel...view more